Generics continues to function as an important, relatively steady profit contributor for Cardinal Health’s CAH Pharma business, even though its revenue impact can be uncertain due to changes in brand pricing, IRA-related adjustments and GLP-1 volumes. In fiscal 2026, generic volume growth exceeded Cardinal Health’s long-term planning assumption of 2-3%, creating what management described as some of the company’s more profitable volume growth. Management expects generic volumes to moderate toward normalized levels in fiscal 2027, but still views the category as a meaningful earnings driver.
The economics are particularly attractive when branded drugs convert to generics. CFO Aaron Alt said Cardinal Health is focused on the profitability associated with generic conversions and noted that the company received an additional benefit from these conversions in the fourth quarter of fiscal 2026.
Management expects some of this benefit to contribute to Pharma segment profit in fiscal 2027. This highlights Cardinal Health’s focus on capturing the profitability benefits of generic conversions while maintaining attractive margins as its product mix changes.
The Red Oak-enabled generics program provides another layer of consistency. Cardinal Health expects fiscal 2027 to benefit from new generic item launches, including fiscal 2026 carryover products, alongside continued consistent market dynamics within the Red Oak program. The company also maintains a strategic relationship with CVS through Red Oak, reinforcing the program’s importance within its broader pharmaceutical ecosystem.
Overall, generics appears to be a stable margin contributor rather than a headline growth engine. With Pharma segment profit expected to grow 8-11% in fiscal 2027, continued strength in generic and brand volumes is explicitly identified as a key driver. The combination of higher generic volumes, favorable brand-to-generic conversions and stable Red Oak market dynamics should therefore continue to support Pharma profitability, even as revenue growth normalizes.
Peer Updates
McKesson’s MCK generics portfolio remained a meaningful contributor to North American Pharmaceutical profitability in the first quarter of fiscal 2027. Prescription transaction volumes increased 5%, although revenues were partly constrained by branded-to-generic conversions. Those conversions supported gross profit, while the timing of new branded and generic product launches helped drive the segment’s 19% operating-profit growth to $894 million. Management also highlighted the strength of ClarusONE, McKesson’s generic sourcing program, which continues to create customer value and support supply stability. Although the company did not disclose a standalone generic margin, management noted that product mix, including generics, influences segment margins, as operating profit grew substantially faster than revenues.
Cencora COR emphasizes broader pharmaceutical distribution, specialty growth and biosimilars. U.S. Healthcare Solutions revenues increased 5% to $74.9 billion, while operating income rose 16% to $966 million, with strength in specialty and underlying utilization supporting profitability.
Management specifically characterized Part B biosimilars as an incremental profit opportunity, given Cencora’s larger role through distribution, GPO and MSO services surrounding physician-administered products. By contrast, Part D biosimilar conversions can reduce revenues with less meaningful profit improvement. Thus, Cencora’s generics-related earnings opportunity appears more service- and mix-driven than volume-driven.
CAH’s Price Performance, Valuation and Estimates
Shares of CAH have gained 19.4% so far this year compared with the industry’s 6.5% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, Cardinal Health trades at a forward price-to-earnings ratio of 19.2X, above the industry average. However, it is trading lower than its five-year high of 22.19X. CAH carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Cardinal Health’s fiscal 2027 earnings implies an 11.5% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
McKesson Corporation (MCK): Free Stock Analysis Report
Cencora, Inc. (COR): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).